Shares Outstanding Shares Outstanding n/a Close	66.53M
Shares Change (YoY) Shares Change (YoY) n/a Close	48.74%
Shares Change (QoQ) Shares Change (QoQ) n/a Close	0.01%
Owned by Institutions (%) Owned by Institutions (%) n/a Close	59.94%
Shares Floating Shares Floating n/a Close	60.75M
Failed to Deliver (FTD) Shares Failed to Deliver (FTD) Shares n/a Close	25,269
FTD / Avg. Volume FTD / Avg. Volume n/a Close	2.12%

Short Selling Information

The latest short interest is 17.29M, so 25.99% of the outstanding shares have been sold short.

Short Interest Short Interest n/a Close	17.29M
Short % of Shares Out Short % of Shares Out n/a Close	25.99%
Short % of Float Short % of Float n/a Close	26.68%
Short Ratio (days to cover) Short Ratio (days to cover) n/a Close	14.55

Valuation Ratios

The PE ratio is -4.55 and the forward PE ratio is -3.19. Cardiff Oncology's PEG ratio is -2.12.

PE Ratio PE Ratio n/a Close	-4.55
Forward PE Forward PE n/a Close	-3.19
PS Ratio PS Ratio n/a Close	302.78
Forward PS Forward PS n/a Close	1.9
PB Ratio PB Ratio n/a Close	2.49
P/FCF Ratio P/FCF Ratio n/a Close	-5.47
PEG Ratio PEG Ratio n/a Close	-2.12

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Cardiff Oncology.

EV / Sales EV / Sales n/a Close	n/a
EV / EBITDA EV / EBITDA n/a Close	n/a
EV / EBIT EV / EBIT n/a Close	n/a
EV / FCF EV / FCF n/a Close	n/a

Financial Position

The company has a current ratio of 7.08, with a Debt / Equity ratio of 0.02.

Current Ratio Current Ratio n/a Close	7.08
Quick Ratio Quick Ratio n/a Close	7.08
Debt / Equity Debt / Equity n/a Close	0.02
Debt / EBITDA Debt / EBITDA n/a Close	-0.03
Debt / FCF Debt / FCF n/a Close	-0.04
Interest Coverage Interest Coverage n/a Close	0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity Return on Equity n/a Close	n/a
Return on Assets Return on Assets n/a Close	n/a
Return on Invested Capital Return on Invested Capital n/a Close	n/a
Revenue Per Employee Revenue Per Employee n/a Close	$21,343.75
Profits Per Employee Profits Per Employee n/a Close	$-1,419,718.75
Employee Count Employee Count n/a Close	32
Asset Turnover Asset Turnover n/a Close	0.01
Inventory Turnover Inventory Turnover n/a Close	n/a

Taxes

Income Tax Income Tax n/a Close	-24K
Effective Tax Rate Effective Tax Rate n/a Close	0.05%

Stock Price Statistics

The stock price has increased by 41.89% in the last 52 weeks. The beta is 1.56, so Cardiff Oncology's price volatility has been higher than the market average.

Beta Beta n/a Close	1.56
52-Week Price Change 52-Week Price Change n/a Close	41.89%
50-Day Moving Average 50-Day Moving Average n/a Close	3.12
200-Day Moving Average 200-Day Moving Average n/a Close	3.31
Relative Strength Index (RSI) Relative Strength Index (RSI) n/a Close	44.81
Average Volume (20 Days) Average Volume (20 Days) n/a Close	1,194,511

Income Statement

In the last 12 months, Cardiff Oncology had revenue of 683K and earned -45.43M in profits. Earnings per share was -0.95.

Revenue Revenue n/a Close	683K
Gross Profit Gross Profit n/a Close	279K
Operating Income Operating Income n/a Close	-48.65M
Net Income Net Income n/a Close	-45.43M
EBITDA EBITDA n/a Close	-48.25M
EBIT EBIT n/a Close	-48.65M
Earnings Per Share (EPS) Earnings Per Share (EPS) n/a Close	-0.95

Full Income Statement

Balance Sheet

The company has 51.47M in cash and 1.52M in debt, giving a net cash position of 49.95M.

Cash & Cash Equivalents Cash & Cash Equivalents n/a Close	51.47M
Total Debt Total Debt n/a Close	1.52M
Net Cash Net Cash n/a Close	49.95M
Retained Earnings Retained Earnings n/a Close	-384.18M
Total Assets Total Assets n/a Close	84.81M
Working Capital Working Capital n/a Close	69.42M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -37.69M and capital expenditures -80K, giving a free cash flow of -37.77M.

Operating Cash Flow Operating Cash Flow n/a Close	-37.69M
Capital Expenditures Capital Expenditures n/a Close	-80K
Free Cash Flow Free Cash Flow n/a Close	-37.77M
FCF Per Share FCF Per Share n/a Close	-0.79

Full Cash Flow Statement

Margins

Gross margin is 40.85%, with operating and profit margins of -7123.13% and -6651.68%.

Gross Margin Gross Margin n/a Close	40.85%
Operating Margin Operating Margin n/a Close	-7123.13%
Pretax Margin Pretax Margin n/a Close	-6655.2%
Profit Margin Profit Margin n/a Close	-6651.68%
EBITDA Margin EBITDA Margin n/a Close	-7063.98%
EBIT Margin EBIT Margin n/a Close	-7123.13%
FCF Margin FCF Margin n/a Close	-5530.45%

Dividends & Yields

CRDF does not appear to pay any dividends at this time.

Dividend Per Share Dividend Per Share n/a Close	n/a
Dividend Yield Dividend Yield n/a Close	n/a
Dividend Growth (YoY) Dividend Growth (YoY) n/a Close	n/a
Payout Ratio Payout Ratio n/a Close	n/a
Earnings Yield Earnings Yield n/a Close	n/a
FCF Yield FCF Yield n/a Close	n/a

Dividend Details

Analyst Forecast

The average price target for CRDF is $9, which is 185.7% higher than the current price. The consensus rating is "Buy".

Price Target Price Target n/a Close	$9
Price Target Difference Price Target Difference n/a Close	185.7%
Analyst Consensus Analyst Consensus n/a Close	Buy
Analyst Count Analyst Count n/a Close	4

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value Lynch Fair Value n/a Close	n/a
Lynch Upside Lynch Upside n/a Close	n/a
Graham Number Graham Number n/a Close	n/a
Graham Upside Graham Upside n/a Close	n/a

Stock Splits

The last stock split was on Feb 20, 2019. It was a backward split with a ratio of 1:6.

Last Split Date Last Split Date n/a Close	Feb 20, 2019
Split Type Split Type n/a Close	backward
Split Ratio Split Ratio n/a Close	1:6

Scores

Altman Z-Score Altman Z-Score n/a Close	1.54
Piotroski F-Score Piotroski F-Score n/a Close	2